Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease

Movement Disorders

Volumn 15, Issue 2, 2000, Pages 305-308

  Zesiewicz, Theresa A ^a   Helal, Mohammed ^a   Hauser, Robert A ^a,b,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Parkinson's Dis Movement Disord C   (United States)

Author keywords

Erectile dysfunction; Impotence; Parkinson's disease; Sexual function; Sildenafil citrate; Viagra

Indexed keywords

AMANTADINE; ATENOLOL; CARBIDOPA PLUS LEVODOPA; PERGOLIDE; PHOSPHODIESTERASE INHIBITOR; PRAMIPEXOLE; ROPINIROLE; SILDENAFIL; TOLCAPONE;

AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; HYPERTENSION; MALE; ORGASM; PARKINSON DISEASE; PENIS ERECTION; PRIORITY JOURNAL; RATING SCALE; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; STATISTICAL ANALYSIS;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMPOTENCE; LIBIDO; MALE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PENILE ERECTION; PHOSPHODIESTERASE INHIBITORS; PILOT PROJECTS; PIPERAZINES; TREATMENT OUTCOME;

EID: 0034022209     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200003)15:2<305::AID-MDS1015>3.0.CO;2-W     Document Type: Article

References (30)

1. NIH Consensus Conference NIH Consensus Development Panel on Impotence. Impotence. JAMA 1993;270:83-90.
2. Shabsigh R, Fishman IJ, Scott FB. Evaluation of erectile impotence. Urology 1988;32:83-90.
3. Furlow WL. Prevalence of impotence in United States. Medical Aspects of Human Sexuality 1985;19:13-16.
4. Burguera JA, Garcia RL, Martinez Agullo E. Disfuncion sexual en la enfermedad de Parkinson. Neurologia 1994;9:178-181.
5. Singer C, Weiner WJ, Sanchez-Ramos J, Ackerman M. Sexual function in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:942.
6. Brown RG, Jahanshahi M, Quinn N, Marsden CD. Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry 1990;53:480-486.
7. Longstreth WR Jr, Linde M. Sickness Impact Profile in Parkinson's disease. Neurology 1984;34(suppl 1):207-208.
8. Lipe H, Longstreth WT, Bird RD, Linde M. Sexual function in married men with Parkinson's disease compared to married men with arthritis. Neurology 1990;40:1347-1349.
9. Cleeves L, Findley LJ. Bromocriptine induced impotence in Parkinson's disease. BMJ 1987;295:367-368.
10. Karacan I, Moore C. Nocturnal penile tumescence: an objective diagnostic aid for erectile dysfunction. In: Bennett AH, ed. Management of Male Impotence. Baltimore, MD: Williams & Wilkins, 1982:63.
11. Burnett AL. Role of nitric oxide in the physiology of erection. Biol Reprod 1995;52:485-489.
12. Marks LS, Duda C, Dorey FJ, Macairan ML, Santos PB. Treatment of erectile dysfunction with sildenafil. Urology 1999;53:19-24.
13. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA, for the Sildenafil Study Group. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-1403.
14. Rosen RC, Capelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319-326.
15. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. In: Pichot P, ed. Psychological Measurements in Psychopharmacology, vol 7. Paris: Kargel-Basel, 1974.
16. Kinsey AC, Pomeroy WB, Martin CE. Sexual Behaviour in the Human Male. Philadelphia, PA: WB Saunders, 1948.
17. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996;78:257-261.
18. Hatzichristou DG. Current treatment and future perspectives for erectile dysfunction. Int J Impot Res 1998;10:S3-13.
19. Rust J, Golombok S. The Golombok Rust Inventory of Sexual Satisfaction. Windsor: NFER-Nelson, 1986.
20. Appenzeller O, Goss JE. Autonomic deficits in Parkinson's syndrome. Arch Neurol 1971;24:50-57.
21. Gotham AM, Brown RG, Marsden CD. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 1986;49:381-389.
22. Brown RG, MacCarthy B, Gotham AM, Der GJ, Marsden CD. Depression and disability in Parkinson's disease: a follow-up of 132 cases. Psychol Med 1988;18:49-55.
23. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995;75:191-236.
24. Rajfer J, Aronson WJ, Bush PA, Dorey F, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992;326:90-94.
25. Derry FA, Dinsmore WW, Fraser M, et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998;51:1629-1633.
26. Steers WD. Meta-analysis of the efficacy of sildenafil (Viagra) in the treatment of severe erectile dysfunction. J Urol 1998;159 (suppl):238.
27. Goldenberg MM. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther 1998;20:1033-1048.
28. Cheitlin MD, Hutter AM, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999;33:273-282.
29. Shah PK. Sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;339:699.
30. Saldana MJ, Villaran C, Alhalel B. Sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998:339;701-702.